YauponYaupon CompanyYaupon Investigational DrugYaupon NewsYaupon Contact Us  
       
       
   
 
 
     
  Top News  
  RSS Feed  
     

MEDIA INQUIRIES
Mike Beyer
Sam Brown Inc.
Phone: 773-463-4211
beyer@sambrown.com 
 

 


August 11, 2011

Yaupon Therapeutics, Inc. Secures $14.4 Million in Series D Financing

MALVERN, PA (August 11, 2011) – Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that it has raised $14.4 million through a Series D private placement of preferred stock.  The new round includes prior investors Vivo Ventures, Palo Alto Investors and Burrill & Company, plus new investor, Aperture Venture Partners. 

Yaupon recently submitted a New Drug Application (NDA) to the FDA for a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).  

“This financing provides us with the necessary capital to take us through the NDA regulatory review process, while preparing for commercialization either alone or with an industry partner,” said Yaupon Chairman and CEO Steve Tullman. “We appreciate the strong support of existing and new investors and their ongoing confidence in the potential of our product for the treatment of this common type of CTCL.”

About Yaupon Therapeutics

Yaupon Therapeutics, a privately held, specialty pharmaceutical company, is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL). If approved, Yaupon’s investigational drug would be the first topical mechlorethamine gel widely available to treat the signs and symptoms of this rare cancer. Please visit the new Yaupon website www.yaupontherapeutics.com for more information.

# # #


 

 
   
     
 
   
   
   
   
         
print page